SAHA (suberoylanilide hydroxamic acid) is a potent inhibitor of class I and class II histone deacetylases (HDACs). This compound inhibits the activities of HDAC1 and HDAC3 (IC50 = 10 nM and 20 nM, respectively; Richon et al.). SAHA exhibits antiproliferative properties and can cause cell cycle arrest at G1 (Marks & Breslow).
REPROGRAMMING · Improves reprogramming efficiency from human and mouse somatic to induced pluripotent stem cells (Huangfu et al.).
CANCER RESEARCH · Downregulates homologous recombination and leads to apoptosis in ovarian cancer cells when used in combination with olaparib (Konstantinopoulos et al.).
· SAHA downregulates Nanog expression, which leads to proliferation inhibition in head and neck cancer stem cells (Kumar et al.).
未找到
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Thank you for your interest in IntestiCult™ Organoid Growth Medium (Human). Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they
can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our
privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.